Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Driving performance after CannEpil versus placebo
ACTRN12619000932167Phase 3Not yet recruiting
- Sponsor
- Cannvalate
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of CannEpil (2 arms), sponsored by Cannvalate. Primary endpoint: Difference in standard deviation of the lateral position. Planned start Aug 2019; status: not yet recruiting.
02
Drugs
CannEpil
Beyond the preview
Go deeper on ACTRN12619000932167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000932167.